Developing game changing treatments and cell therapies for severe diseases

We develop and commercialize innovative treatments for patients with severe and life-threatening conditions. Our products have the potential to improve outcomes in the treatment of neurological and opthalmic disease and for ground-breaking regenerative cell therapies. They give hope for patients lacking satisfactory alternatives.


“We are very excited about the clinical potential for ILB, which may prove to be a game changing treatment for many devastating diseases.”

Professor Ann Logan,
Scientific Director, Neuregenix Ltd.


January 7, 2021
TIKOMED’S ILB® resolves inflammatory scarring and promotes functional tissue repair in data published in npj Regenerative Medicine
Viken – 7 January 2021 – A new study on TIKOMED’s lead drug candidate, ILB®, was published in npj Regenerative Medicine today. The peer-reviewed data from rodent and human disease models showed that ILB® leads to tissue remodelling, reduced fibrosis and functional tissue regeneration – observations indicating the potential of ILB® to alleviate fibrotic diseases. …
Read More
October 9, 2020
Update regarding our Amyotrophic Lateral Sclerosis (ALS) study conducted at Sahlgrenska University Hospital in Gothenburg, Sweden
Our Phase IIa clinical trial evaluating the safety, tolerability and possible efficacy of subcutaneous injections of ILB® in ALS is finalized and has been reported to the Swedish Medical Products Agency. The results indicate that, for the variants of ALS and the given dose investigated in the study, ILB® seems to have beneficial clinical effects…
Read More
September 14, 2020
TIKOMED’S ILB® restores brain energy metabolism following severe traumatic brain injury in the rat demonstrated in data published by the journal Antioxidants
Viken – 14th September 2020 – A new study on TIKOMED’s lead drug candidate, ILB®, addressing one of the underlying causes of neurodegeneration in acute and chronic diseases was published in Antioxidants today. The data from the rodent model studying severe traumatic brain injury (sTBI), showed that a single post-injury injection of ILB® has beneficial…
Read More
August 28, 2020
TIKOMED granted Orphan Medicinal Drug Designation for ILB® for the treatment of amyotrophic lateral sclerosis by the European Commission
Viken – 28th August 2020 – TIKOMED, a Swedish privately-held biopharmaceutical company today announced that the European Commission has granted Orphan Drug Designation to its lead drug candidate ILB® for the treatment of patients with amyotrophic lateral sclerosis (ALS) – a terminal, neurodegenerative disease where most patients die of respiratory muscle weakness in less than…
Read More